Skip to content

Treatment of gastric precancerous change by Celecoxib: A clinical control study

Treatment of gastric precancerous change by Celecoxib: A clinical control study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNRC-08000150
Enrollment
Unknown
Registered
2008-10-05
Start date
2007-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic atrophic gastritis

Interventions

Celecoxib group:Celecoxib 200mg, bid, x3m
Combine group:Celecoxib 200mg, bid, x3m, Amoxicillin 500mg, bid, x1w
Klaricid 500mg, bid, x1w
Nexium 40mg, qd, x1w
Anti-HP group:Amoxicillin 500mg, bid, x1w

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age<65; 2. Chronic atrophic gastritis diagnosed by upper gastrointestinal endoscopy and histology test once before or for the first time in our hospital; 3. Willing to take the follow-up investigation, sign informed consent documents; 4. Normal client with tolerable digestive symptom, without problem through brief physical examination; 5. Normal digestive test results like enteroscopy, ultrasound, capsule endoscopy, et al; 6. Without diabetes, disease and dysfunction in cardiovascular, respiratory, urinary, nervous system and systemic inflammatory, in a stressless condition.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactating mother; 2. Active peptic ulcer; 3. Previous gastrectomy; 4. Suspected or confirmed cancer(gastric cancer included); 5. Allergy to prescribed medication; 6. Concomitant use of other antibiotics, proton pump inhibitors, H2 receptor antagonists or non-steroidal anti-inflammatory drugs over last 4weeks; 7. Can not stand endoscopy; 8. Cardiovascular and cerebrovascular disease; 9. Abnormal in biochemistry test.

Design outcomes

Primary

MeasureTime frame
Biochemical indicator;Histological indicato;

Secondary

MeasureTime frame
Quality of life;

Countries

China

Contacts

Public ContactTang cheng-wei
cwtang@medmail.com.cn+86 28 81812275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026